Compare · AMGN vs REPL
AMGN vs REPL
Side-by-side comparison of Amgen Inc. (AMGN) and Replimune Group Inc. (REPL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and REPL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $197.69B, about 230.2x REPL ($859.0M).
- Over the past year, AMGN is up 23.9% and REPL is down 17.0% - AMGN leads by 40.8 points.
- REPL has been more active in the news (6 items in the past 4 weeks vs 1 for AMGN).
- Both have 25 recent analyst ratings on file.
- Company
- Amgen Inc.
- Replimune Group Inc.
- Price
- $366.18-1.45%
- $10.23+7.51%
- Market cap
- $197.69B
- $859.0M
- 1M return
- +5.29%
- +16.70%
- 1Y return
- +23.85%
- -16.99%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2018
- News (4w)
- 1
- 6
- Recent ratings
- 25
- 25
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest AMGN
- FDA Approval for REPATHA issued to AMGEN INC
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
Latest REPL
- SEC Form PRE 14A filed by Replimune Group Inc.
- Replimune upgraded by BMO Capital Markets with a new price target
- SEC Form S-8 filed by Replimune Group Inc.
- SEC Form 10-K filed by Replimune Group Inc.
- Replimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
- Replimune upgraded by Analyst with a new price target
- Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
- Chief Commercial Officer Sarchi Christopher sold $110,880 worth of shares (12,000 units at $9.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 180,962 units (SEC Form 4)